Evotec (EVO) Competitors

Evotec (NASDAQ:EVO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Which has more risk & volatility, EVO or RYTM?

Evotec has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.

Which has stronger earnings and valuation, EVO or RYTM?

Evotec has higher revenue and earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$788.22M	1.72	-$212.18M	N/A	N/A
Rhythm Pharmaceuticals	$156.29M	41.59	-$260.60M	-$3.01	-32.51

Does the media refer more to EVO or RYTM?

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Evotec. MarketBeat recorded 20 mentions for Rhythm Pharmaceuticals and 9 mentions for Evotec. Rhythm Pharmaceuticals' average media sentiment score of 1.05 beat Evotec's score of 0.49 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is EVO or RYTM more profitable?

Evotec has a net margin of -26.34% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Evotec's return on equity of -21.51% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.34%	-21.51%	-10.54%
Rhythm Pharmaceuticals	-117.13%	-1,831.43%	-48.33%

Do institutionals & insiders have more ownership in EVO or RYTM?

5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts recommend EVO or RYTM?

Evotec presently has a consensus price target of $5.90, indicating a potential upside of 54.86%. Rhythm Pharmaceuticals has a consensus price target of $101.57, indicating a potential upside of 3.79%. Given Evotec's higher possible upside, equities analysts plainly believe Evotec is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rhythm Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Summary

Rhythm Pharmaceuticals beats Evotec on 8 of the 15 factors compared between the two stocks.